Forbes September 1, 2022
In the debate on the drug pricing provisions contained in the Inflation Reduction Act, critics call the government-mandated process “price controls.” Specifically, they’re referring to the relatively small number of drugs that will be selected for price negotiation with the Centers for Medicare and Medicaid Services (CMS).
Starting in 2026, 10 Medicare Part D (outpatient) drugs will have a Medicare-negotiated price. This number will rise to 15 Part D drugs in 2027, 15 Part B (physician-administered) and D drugs in 2028, and 20 Part B and D drugs in 2029 and beyond. To be selected for negotiation, small molecule drugs must be 9 years post launch and not face generic competition, and large molecule biologics must be 13 years post...
Today's Sponsors
Today's Sponsor